Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mucin hypersecreting neoplasms.

D L Carr-Locke1

  • 1Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 7, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypotension during ERCP is common but not a risk factor for post-ERCP pancreatitis.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2008
Same author

Endoscopic pH monitoring for patients with suspected or refractory gastroesophageal reflux disease.

Canadian journal of gastroenterology = Journal canadien de gastroenterologie·2007
Same author

Endoluminal gastroplication for treatment of patients with classic gastroesophageal reflux symptoms and borderline 24-h pH studies.

Scandinavian journal of gastroenterology·2004
Same author

Safety of ERCP during pregnancy.

The American journal of gastroenterology·2003
Same author

Bedside scoring system to predict the risk of developing pancreatitis following ERCP.

Endoscopy·2002
Same author

Gastrointestinal stromal sarcoma--a case report of palliative enteral stenting.

Singapore medical journal·2002
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Mucinous pancreatic neoplasms, including mucinous cystic neoplasms and intraductal mucin hypersecreting neoplasms (IMHN), are distinct but share features. Both are treated with surgery and are less aggressive than typical pancreatic cancer.

Area of Science:

  • Gastroenterology
  • Oncology
  • Pathology

Background:

  • Mucinous pancreatic neoplasms are uncommon and include mucinous cystic neoplasms (MCNs) and intraductal mucin hypersecreting neoplasms (IMHN).
  • MCNs and IMHN share similarities in histology and mucin production, often mimicking pancreatic pseudocysts.
  • Despite shared features, they are distinct clinico-pathologic entities with differing tumor growth patterns.

Purpose of the Study:

  • To differentiate between mucinous cystic neoplasms and intraductal mucin hypersecreting neoplasms (IMHN).
  • To highlight the distinct clinical and pathological features of these uncommon pancreatic tumors.
  • To inform diagnostic and treatment strategies for mucinous pancreatic neoplasms.

Main Methods:

  • Comparative analysis of clinico-pathologic features of MCNs and IMHN.

Related Experiment Videos

  • Review of histopathology, mucin production, and imaging characteristics (ERCP, pancreatography).
  • Assessment of tumor behavior and treatment outcomes (surgical resection).

    • Main Results:

    • IMHN exhibits intraductal growth and mucin hypersecretion, causing pancreatic duct ectasia with characteristic ERCP findings.
    • MCNs involve peripheral ducts, forming cysts that do not communicate with the main pancreatic duct, thus not visualized on pancreatography.
    • Both MCNs and IMHN show a less aggressive clinical course compared to ductal adenocarcinomas and are managed by surgical resection.

    Conclusions:

    • Mucinous cystic neoplasms and IMHN are distinct entities despite overlapping features.
    • Diagnostic differentiation relies on understanding their unique growth patterns and imaging findings.
    • Surgical resection remains the standard treatment for both types of mucinous pancreatic neoplasms.